Werbung
Werbung

IPSC

IPSC logo

Century Therapeutics, Inc. Common Stock

1.94
USD
Gesponsert
+0.17
+9.38%
09. Jan., 15:59 UTC -5
Geschlossen
exchange

Vor-Markt

1.88

-0.06
-3.04%

IPSC Ergebnisberichte

Positives Überraschungsverhältnis

IPSC übertreffen die 11 der letzten 18Schätzungen.

61%

Nächster Bericht

Datum des nächsten Berichts
02. März 2026
Estimate for Q4 25 (Revenue/ EPS)
--
/
-$0.26
Implizierte Änderung von Q3 25 (Revenue/ EPS)
--
/
-18.75%
Implizierte Änderung von Q4 24 (Revenue/ EPS)
-100.00%
/
-39.53%

Century Therapeutics, Inc. Common Stock earnings per share and revenue

On 13. Nov. 2025, IPSC reported earnings of -0.32 USD per share (EPS) for Q3 25, beating the estimate of -0.34 USD, resulting in a 7.06% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -17.54% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 7 analysts forecast an EPS of -0.26 USD, with revenue projected to reach -- USD, implying an decrease of -18.75% EPS, and increase of 0.00% in Revenue from the last quarter.
FAQ
For Q3 2025, Century Therapeutics, Inc. Common Stock reported EPS of -$0.32, beating estimates by 7.06%, and revenue of $0.00, 0% as expectations.
The stock price moved down -17.54%, changed from $0.56 before the earnings release to $0.46 the day after.
The next earning report is scheduled for 02. März 2026.
Based on 7 analysts, Century Therapeutics, Inc. Common Stock is expected to report EPS of -$0.26 and revenue of -- for Q4 2025.
Scheck FXEmpire's Earnings Calendar for today's list of reporting companies.
Werbung